From 1 September 2024, Swissmedic is accepting electronic data sets from pivotal bioequivalence studies for applications for new authorisation of human medicinal products with known active substances without innovation
From 1 September 2024, Swissmedic is accepting SEND data sets for applications for new authorisation for human medicinal products with new active substances
Additional accompanying documentation for applications for authorisation and variation for medicinal products can now be submitted directly via the eGov portal with immediate effect
